Caris Life Sciences (CAI) Cost of Revenue (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Cost of Revenue of $1.9 million for Q1 2026, down 96.81% year-over-year from $60.9 million in Q1 2025, and down 99.24% quarter-over-quarter from $254.7 million in Q4 2025.
Caris Life Sciences (CAI) Cost of Revenue (2024 - 2026) Analysis & Trends
Caris Life Sciences' Cost of Revenue history runs 3 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Cost of Revenue fell 96.81% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $388.9 million (up 218.66% YoY), while the FY2025 annual figure was $262.4 million, up 2421.9% from the prior year.
- Cost of Revenue for Q1 2026 stood at $1.9 million, down from $254.7 million in the prior quarter.
- The five-year high for Cost of Revenue was $254.7 million in Q4 2025, with the low at $1.9 million in Q1 2026.
- The 3-year median for Cost of Revenue is $57.9 million (2024), against an average of $63.9 million.
- The sharpest annual moves came in 2025 and 2026: Cost of Revenue jumped 7680.48% in 2025, then tumbled 96.81% in 2026.
- Caris Life Sciences' Cost of Revenue stood at $3.3 million in 2024, then surged by 7680.48% to $254.7 million in 2025, then sank by 99.24% to $1.9 million in 2026.
- Business Quant data shows CAI's Cost of Revenue at $1.9 million in Q1 2026, $254.7 million in Q4 2025, and $67.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | 81.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81.33 Mn |
| Jun 30, 2026 | 81.33 Mn |
| Mar 31, 2026 | 1.94 Mn |
| Mar 31, 2026 | 1.94 Mn |
| Dec 31, 2025 | 254.66 Mn |
| Dec 31, 2025 | 254.66 Mn |
| Sep 30, 2025 | 66.98 Mn |
| Sep 30, 2025 | 66.98 Mn |
| Jun 30, 2025 | 65.32 Mn |
| Jun 30, 2025 | 65.32 Mn |
| Mar 31, 2025 | 60.89 Mn |
| Mar 31, 2025 | 60.89 Mn |
| Dec 31, 2024 | 3.27 Mn |
| Dec 31, 2024 | 3.27 Mn |
| Sep 30, 2024 | 54.81 Mn |
| Sep 30, 2024 | 54.81 Mn |
| Jun 30, 2024 | 3.06 Mn |
| Jun 30, 2024 | 3.06 Mn |